Group 1 - The core point of the article is that Haili Biological announced a board meeting to discuss adjustments to the transaction price for a major asset purchase and the signing of a supplementary agreement [1] - For the fiscal year 2024, Haili Biological's revenue composition is as follows: medical devices account for 57.81%, veterinary biological products account for 42.19%, and other businesses account for 0.01% [1] - As of the report date, Haili Biological has a market capitalization of 4.6 billion yuan [1] Group 2 - A significant breakthrough has been recognized for a new drug in China, which has been acknowledged by both Chinese and American officials for its breakthrough efficacy, generating excitement at the World Lung Cancer Conference [1]

海利生物公告，公司与美伦管理有限公司签订补充协议，调整重大资产购买交易价格。根据北京卓信大 华资产评估有限公司评估，瑞盛生物股东全部权益价值为9.74亿元，比原17亿元下调。因此，交易价格 由9.35亿元调整为5.36亿元，美伦公司将返还交易价格差额3.99亿元。此次调整不影响公司对瑞盛生物 55%股权的持有，有助于降低投资风险和业绩承诺无法达成风险。调整后的2025年和2026年扣非净利润 承诺数分别为5000万元和5800万元。 ...

Core Insights - The animal health sector experienced a 1.14% increase on September 15, with BioShares leading the gains [1] - The Shanghai Composite Index closed at 3860.5, down 0.26%, while the Shenzhen Component Index closed at 13005.77, up 0.63% [1] Stock Performance - BioShares (600201) closed at 8.82, up 7.17% with a trading volume of 624,100 shares and a turnover of 539 million yuan [1] - Dayu Biological (871970) closed at 11.50, up 6.09% with a trading volume of 124,300 shares and a turnover of 139 million yuan [1] - Other notable performers include: - Jinhai Biological (002688) at 7.20, up 3.00% [1] - Ruipu Biological (300119) at 21.98, up 1.76% [1] - Zhongmu Co. (600195) at 7.50, up 1.63% [1] Capital Flow - The animal health sector saw a net outflow of 25.577 million yuan from institutional investors, while retail investors contributed a net inflow of 6.5625 million yuan [2] - The capital flow for individual stocks indicates: - Jinhai Biological had a net inflow of 32.1651 million yuan from institutional investors [3] - Zhongmu Co. had a net inflow of 6.8986 million yuan from institutional investors [3] - Ruipu Biological experienced a net outflow of 1.1475 million yuan from institutional investors [3]

Market Overview - The animal health sector experienced a decline of 0.21% on September 12, with Dayu Biological leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Individual Stock Performance - Shunlian Biological (688098) closed at 11.85, up 2.07% with a trading volume of 85,100 shares and a turnover of 99.05 million yuan [1] - KQ Biological (688526) closed at 18.63, up 0.70% with a trading volume of 19,700 shares and a turnover of 36.27 million yuan [1] - Huisheng Biological (300871) closed at 22.55, up 0.53% with a trading volume of 54,100 shares and a turnover of 122 million yuan [1] - Dayu Biological (871970) led the decline, closing at 10.73, down 3.85% with a trading volume of 76,600 shares and a turnover of 82.31 million yuan [2] Capital Flow Analysis - The animal health sector saw a net outflow of 15.44 million yuan from institutional investors, while retail investors experienced a net outflow of 9.04 million yuan [2] - Speculative funds recorded a net inflow of 24.47 million yuan [2] Detailed Capital Flow for Selected Stocks - Shunlian Biological had a net inflow of 14.94 million yuan from institutional investors, but a net outflow of 21.09 million yuan from retail investors [3] - Huisheng Biological experienced a net outflow of 7.83 million yuan from institutional investors, while retail investors had a net inflow of 9.81 million yuan [3] - KQ Biological saw a net outflow of 1.73 million yuan from institutional investors, with a minor net inflow from retail investors [3]

Core Viewpoint - The animal health sector experienced a rise of 0.92% on September 11, with Dayu Biological leading the gains, while the overall market indices also showed significant increases [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 3875.31, up 1.65%, and the Shenzhen Component Index closed at 12979.89, up 3.36% [1]. - Dayu Biological's stock price increased by 3.81% to 11.16, with a trading volume of 140,500 shares and a transaction value of 158 million [1]. Group 2: Individual Stock Performance - Other notable performers included: - Houfeng Holdings, up 2.75% to 4.11, with a trading volume of 326,800 shares and a transaction value of 133 million [1]. - Keqian Biological, up 2.15% to 18.50, with a trading volume of 32,400 shares and a transaction value of 59.27 million [1]. - Yongshun Biological, up 1.69% to 10.80, with a trading volume of 48,100 shares and a transaction value of 52.46 million [1]. Group 3: Capital Flow Analysis - The animal health sector saw a net outflow of 70.71 million from institutional investors, while retail investors contributed a net inflow of 77.65 million [2][3]. - The capital flow for individual stocks showed varied trends, with significant outflows from stocks like Zhongmu Co., which had a net outflow of 11.86 million from institutional investors [3].

Core Viewpoint - Haili Biological announced that its subsidiary, Ruisheng Biological, has had its Class III medical device "Natural Bone Repair Material" registration application accepted by the National Medical Products Administration, which is expected to enhance its product line in the oral bone defect repair sector [1] Group 1 - The product is designed for maxillary bone defect repair and utilizes a more efficient production process, leading to faster and more stable bone repair outcomes [1] - Approval of the product for market launch will diversify Ruisheng Biological's offerings in the oral bone defect repair field [1]

Group 1 - Dematech won a 900 million yuan overseas smart logistics project from a well-known e-commerce giant in Latin America, focusing on intelligent logistics cross-belt sorting systems and related services [1] - Kang En Bei received approval for the registration of short-term financing bonds and medium-term notes, with a total registration amount of 1 billion yuan, valid for two years [1][2] - Zhi Xiang Jin Tai's GR1803 injection for systemic lupus erythematosus clinical trial has been approved by the National Medical Products Administration [2] Group 2 - Jin Da Wei's subsidiary received approval for a veterinary drug product, pyridone, valid from September 3, 2025, to September 2, 2030 [4] - Fu Li Wang's subsidiary plans to invest 500 million yuan in a high-end wire material project, focusing on high-strength prestressed steel strands for various applications [5] - He Li Biological's subsidiary's Class III medical device registration application has been accepted, focusing on natural bone repair materials [12] Group 3 - Lin Yang Energy won a 244 million yuan metering equipment project from Southern Power Grid, expected to positively impact its 2025 and 2026 performance [20] - Sanxia Water plans to absorb its wholly-owned subsidiary, Chongqing Changdian United Energy, with all assets and liabilities to be inherited by Sanxia Water [13] - Tian Cheng Technology canceled the use of 91 million yuan of raised funds for permanent working capital, ensuring no impact on the normal operation of investment projects [24] Group 4 - Baosteel received approval to publicly issue bonds totaling 20 billion yuan to professional investors, valid for 24 months [52] - Tian Kang Biological reported a 10.15% year-on-year increase in pig sales in August, with a total of 263,800 pigs sold [53] - Xinjiang Construction won multiple major projects totaling 4.506 billion yuan, including a 2.4 billion yuan photovoltaic hydrogen synthesis project [18]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：603718 证券简称：海利生物 公告编号：2025－039 上海海利生物技术股份有限公司 关于控股子公司三类医疗器械注册申请获得受理的公告 上海海利生物技术股份有限公司（以下简称"公司"）控股子公司陕西瑞盛生物 科技有限公司（以下简称"瑞盛生物"）于近日收到国家药品监督管理局（以下简称 "国家药监局"）下发的医疗器械注册申请受理通知信息，现将相关情况公告如下： 一、该医疗器械的基本信息 申请人：陕西瑞盛生物科技有限公司 产品名称：天然骨修复材料 受理号：CQZ2501670 产品类别：第三类医疗器械 二、 目前所处审批阶段 该医疗器械目前注册申请已获得受理。 三、 后续所需审批流程 后续所需的审批流程：审评审批、制证。 临床用途：适用于颌骨缺损修复 异种骨修复材料因其形态和多孔结构与天然骨相似，有利于骨细胞长入及骨组织 分化形成。通过物理化学方法可去除其免疫原性，具备来源广泛、制造成本低、获取 与加工便捷、生物力学性能优良、能被机体吸收降解等优势，在口腔骨修复市 ...

Market Overview - The animal health sector experienced a decline of 0.5% on September 10, with Yongshun Biological leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Stock Performance - Notable gainers included: - Qudongli (838275) with a closing price of 11.21, up 2.75% [1] - *ST Lvkang (002868) at 26.42, up 1.62% [1] - Houfeng Holdings (002141) at 4.00, up 0.76% [1] - Major decliners included: - Yongshun Biological (839729) at 10.62, down 3.28% [2] - Shilian Biological (688098) at 11.72, down 1.76% [2] - Huai Sheng Biological (300871) at 22.20, down 1.60% [2] Capital Flow Analysis - The animal health sector saw a net outflow of 81.6 million yuan from institutional investors, while retail investors contributed a net inflow of 53.0 million yuan [2] - The detailed capital flow for key stocks showed: - Repu Biological (300119) had a net inflow of 1.12 million yuan from retail investors [3] - Kexian Biological (688526) saw a net inflow of 14.78 thousand yuan from institutional investors [3] - Hai Li Biological (603718) experienced a significant net outflow of 22.66 million yuan from institutional investors [3]

Core Viewpoint - Haili Biological (603718.SH) announced that its subsidiary, Shaanxi Ruisheng Biological Technology Co., Ltd., received a medical device registration application acceptance notice from the National Medical Products Administration for a natural bone repair material [1] Company Summary - The product is classified as a Class III medical device under the Medical Device Classification Rules and falls under the category of oral medical devices, specifically for bone filling and repair materials [1] - The product classification code is 17-08-06, indicating its specific use in oral cavity bone defect repair [1] - Once approved, this product will enhance Ruisheng Biological's product line in the field of oral bone defect repair [1]